Study Finds Concerning Trends Among E-cigarette Users in UK

Sep.30.2024
Study Finds Concerning Trends Among E-cigarette Users in UK
A study of 1,020 e-cigarette users found 39% may buy from unregulated sources, raising concerns about safety.

According to a report by Internewscast on September 29th, a study conducted on 1,020 e-cigarette users found that 39% of them admitted that they may purchase e-cigarettes from unregulated channels that have not been officially safety-checked.


The research results also show that one-third of the respondents believe that their nicotine consumption will increase. However, 22% of people believe that the upcoming law will motivate them to quit their e-cigarette habit.


A study commissioned by the nicotine pouch brand Übbs and retailer Haypp, carried out by OnePoll.com, aimed to respond to the UK government's commitment to achieve a "smoke-free Britain". Earlier this year, the UK government announced legislation that will restrict the sale and use of disposable e-cigarettes by 2025.


According to the survey, since the ban on e-cigarettes was announced, 24% of respondents have attempted to quit using them. 26% of respondents have switched to other alternatives, such as traditional cigarettes (36%), nicotine pouches (26%), and gum (25%).


The study also found that 85% of the respondents had smoked before switching to e-cigarettes, with 52% of them expressing concern about reverting to smoking habits after the ban is implemented.


The spokesperson for the Übbs brand, Steve McGeough, stated that,


Hearing e-cigarette users say they will seriously consider switching to smoking after the ban is implemented is really concerning. Additionally, research also shows that some people may even seek unregulated e-cigarettes, which is very worrying in terms of quality and safety. Our research suggests that while disposable e-cigarettes may be gradually phased out, there are still many safe and regulated alternatives available now or when the ban comes into effect. Nicotine pouches are a popular choice, providing support for the UK's goal to become a smoke-free nation.


The study also found that 73% of e-cigarette users have not tried any e-cigarette alternatives. However, among them, 28% are most likely to try traditional cigarettes, 21% are willing to try gum, and 25% are open to trying nicotine pouches.


Additionally, 30% of respondents are "very aware" of the risks of using unregulated e-cigarettes. The most familiar features of such devices among respondents include the lack of nicotine warning labels (41%) and the absence of emissions testing information (30%). When looking for alternatives, 52% of people prioritize the smell and taste of the product, followed by considerations of safety and quality assurance (50%), and the product's discreteness (33%). 30% of individuals prefer products that are "readily available," while 24% believe that open system e-cigarettes are too complicated.


The study also revealed that running out of battery is the most annoying thing when using e-cigarettes (32%), followed by not being able to use them freely anytime and anywhere (30%). Another major concern is having to leave social gatherings to smoke and missing out on time with friends (23%), and the issue of not being able to use e-cigarettes on airplanes (21%).


Haypp spokesperson Markus Lindbald stated,


From a positive perspective, it is a good phenomenon that before the ban is implemented, so many people are trying to quit e-cigarettes or explore other low-risk alternatives, such as nicotine pouches, instead of turning back to smoking. Based on the nearly smokeless experience in Sweden, nicotine pouches can play an important role in reducing smoking rates and improving public and personal health.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
The Global State of Tobacco Harm Reduction, a project operated by Knowledge·Action·Change, estimates that about 200 million people worldwide use non-combustible nicotine products including vapes, heated tobacco, nicotine pouches and snus. Its 2026 report says use of these products rose alongside declining smoking rates in 28 countries it analyzed. The data do not establish that all 200 million users have quit smoking, nor do they prove a direct causal relationship. GSTHR also says regulatory restrictions on the products continue to expand in many markets.
Sep.10
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22